Waldenstrom's Macroglobulinemia Clinical Trial
Official title:
Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown that it can destroy WM cells.
- Sildenafil will be given orally (at home) at a reduced dose for the first week, then
each week for 3 more weeks, the dose will be increased. If the patient has no major
side effects, then they will receive the maximal dose for 2 years. If they have major
side effects, then the dose of the drug might be lowered or the drug stopped.
- Sildenafil will be continued until their is disease progression or serious side
effects.
- While patients are receiving sildenafil, they will be seen in the clinic on months
1,2,9,15 and 21 for blood tests and a subject questionnaire. They will also be seen on
months 3,6,12,18 and 24 for a physical exam, blood test, physical assessment test, CT
scans of chest, abdomen and pelvis, and a subject questionnaire.
- At the end of the study (month 24) a physical exam, blood tests, physical assessment
test and a questionnaire will be conducted.
- Follow-up includes clinic visits at month 27,33,39 and 45 for blood tests and a
questionnaire as well as visits at month 30,36,42 and 48 for physical exam, blood
tests, physical assessment test, bone marrow aspirate and biopsy, CT scans of chest,
abdomen and pelvis, and a questionnaire.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02566265 -
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
|
Phase 2 | |
Completed |
NCT00422656 -
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00150462 -
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
Phase 1 | |
Terminated |
NCT00142168 -
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Suspended |
NCT02439138 -
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
|
Phase 2 | |
Completed |
NCT01470196 -
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00250926 -
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
|
Phase 2 | |
Terminated |
NCT03225716 -
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
|
Phase 1 | |
Terminated |
NCT01744912 -
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT02363439 -
Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
|
Phase 1/Phase 2 | |
Completed |
NCT00976248 -
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Terminated |
NCT00575965 -
Simvastatin in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00919139 -
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
|
N/A | |
Completed |
NCT01614821 -
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Active, not recruiting |
NCT01078974 -
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 1 | |
Completed |
NCT00481871 -
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00142116 -
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT02092909 -
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
|
Phase 1/Phase 2 | |
Completed |
NCT00807677 -
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01046006 -
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
|
Phase 2 |